Ibrutinib API is a pharmaceutical-grade Bruton's Tyrosine Kinase (BTK) inhibitor used in the treatment of various B-cell malignancies. It selectively inhibits BTK, disrupting B-cell receptor signaling and preventing the growth and survival of malignant B lymphocytes.
Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic graft-versus-host disease (cGVHD). It is widely formulated into oral capsule and tablet dosage forms.
Manufactured under WHO-GMP-certified facilities, our Ibrutinib API delivers exceptional purity, stability, and batch-to-batch consistency. Every batch is supplied with comprehensive documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), and Technical Data Sheet (TDS).
Ibrutinib API is used in pharmaceutical formulations for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, and other B-cell malignancies.
Ibrutinib irreversibly inhibits Bruton's Tyrosine Kinase (BTK), blocking B-cell receptor signaling and suppressing the growth and survival of malignant B cells.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation.
Yes. We supply Ibrutinib API in commercial quantities with worldwide export support.
Get Bulk Quote via WhatsApp